Dr. Santosh Kumar, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 572
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 257526
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Hospital S U N Y Health Science Center Syracuse, NY
- St Joseph's Hospital Health Center Syracuse, NY
- Crouse Hospital Syracuse, NY
- Oswego Hospital Oswego, NY
- Samaritan Medical Center Watertown, NY
Medical groups
- Hematology-Oncology Associates of Cny, PC (64 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 572
- Services billed
- 35,096
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,630 | 79 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,275 | 337 |
| Insertion of needle into vein for collection of blood sample | 1,268 | 339 |
| Blood test, comprehensive group of blood chemicals | 1,076 | 309 |
| Established patient office or other outpatient visit, 30-39 minutes | 585 | 292 |
| Gammaglobulin (immune system protein) measurement | 373 | 78 |
| Established patient office or other outpatient visit, 20-29 minutes | 231 | 211 |
| Ferritin (blood protein) level | 218 | 129 |
| Established patient office or other outpatient visit, 40-54 minutes | 217 | 114 |
| Iron binding capacity | 207 | 125 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 38 payments worth $20,924 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $6,875 |
|---|---|
| Exelixis Inc. | $3,948 |
| Pfizer Inc. | $3,712 |
| Geron Corporation | $3,551 |
| Novartis Pharmaceuticals Corporation | $1,463 |
| Daiichi Sankyo Inc. | $650 |
| Gilead Sciences, Inc. | $450 |
| Cardinal Health 110 LLC | $275 |
| Consulting Fee | $11,793 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,500 |
| Travel and Lodging | $2,688 |
| Honoraria | $1,975 |
| Food and Beverage | $969 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 13, 2025 | Compensation for services other than consulting (speaking, faculty) TIVDAK · ONCOLOGY | $3,500 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Consulting Fee IMFINZI · Oncology | $2,475 |
| Geron Corporation Dec 4, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,080 |
| Exelixis Inc. Jun 26, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,975 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Consulting Fee IMFINZI · Oncology | $1,925 |
| Novartis Pharmaceuticals Corporation Dec 3, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,463 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Consulting Fee IMFINZI · Oncology | $1,375 |
| AstraZeneca Pharmaceuticals LP Jun 18, 2025 | Consulting Fee IMFINZI · Oncology | $1,100 |
| Exelixis Inc. Jun 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $717 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Geron Corporation Dec 4, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,080 |
| Geron Corporation Dec 4, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to BOSTON, MA | $405 |
| Geron Corporation Dec 4, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to BOSTON, MA | $9.32 |
| Novartis Pharmaceuticals Corporation Dec 3, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,463 |
| Geron Corporation Nov 8, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to BOSTON, MA | $650 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Consulting Fee IMFINZI · Oncology | $1,375 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Consulting Fee IMFINZI · Oncology | $2,475 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Consulting Fee IMFINZI · Oncology | $1,925 |
| Exelixis Inc. Jun 26, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,975 |
| Exelixis Inc. Jun 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind | $717 |
| Exelixis Inc. Jun 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC | $532 |
| Exelixis Inc. Jun 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC | $163 |
| AstraZeneca Pharmaceuticals LP Jun 18, 2025 | Consulting Fee IMFINZI · Oncology | $1,100 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Gilead Sciences, Inc. Apr 3, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4147065;VEM US;10716362 | $450 |
| Pfizer Inc. Jan 17, 2025 | Travel and Lodging TIVDAK · ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind | $212 |
| Pfizer Inc. Jan 13, 2025 | Compensation for services other than consulting (speaking, faculty) TIVDAK · ONCOLOGY | $3,500 |
| Cardinal Health 110 LLC Jan 9, 2025 | Consulting Fee | $275 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $136,159 in research payments for these studies, mostly to the institutions running them.
- A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarci…
Merck Sharp & Dohme LLC - A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-…
Merck Sharp & Dohme LLC - A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Ad…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.